The mental health community has been looking for a medication more modern, providing quality of life to patients. Seroquel has been that medication.
The surge in sales of Seroquel by Astra-Zeneca was somewhat anticipated. It is surprising the company would ignore such drug interactions that would ultimately give the drug a bad name.
Seroquel is used widely across most age groups, so the damage to the addicts of heroine seeking help through methadone substitution reaches from young to old. Astra-Zeneca was completely reckless in concealing such information. The majority of patients benefiting from Seroquel are not drug addicts. None of it makes sense.
This is what happens when hapless CEOs run a drug company. They are interested in market forces and bonuses; not the PURPOSE of the company in the first place.
Bonuses should be outlawed.
C21H27NO
December 15, 2017
By Sam Roe
Few prescription drugs (click here) were as popular as the antipsychotic Seroquel. Psychiatrists trusted it, nursing homes used it and addiction specialists prescribed it. Annual sales exceeded $3 billion.
But in the winter of 2009, one of the top pharmaceutical sales representatives selling it, Allison Zayas, began to have her doubts.
According to Zayas, one of her best clients, a doctor at a New York City outpatient clinic, told her that a patient had died while taking the drug and that the combination of Seroquel and methadone might have played a role.
Allison Zayas carried a conscience with her sales pitch. Besides, Seroquel practically sold itself. The CEO should be indicted on criminal charges. The MDs treating these patients wanted QUALITY OF LIFE, not end of life.
Allison Zayas carried a conscience with her sales pitch. Besides, Seroquel practically sold itself. The CEO should be indicted on criminal charges. The MDs treating these patients wanted QUALITY OF LIFE, not end of life.
Soon after, Zayas recalled, two other doctors told her as many as 10 patients at New York methadone clinics had died taking Seroquel and methadone together. Zayas said she reported the deaths to her company, drugmaker AstraZeneca, but that it continued to aggressively market the blockbuster drug, even to methadone clinics.
"Their goal was to get in there and sell Seroquel," she told the Tribune in an interview. "It was not, 'Let's draw back. Let's take a look at the information.' It was, 'Get in there and sell.' Everything is sell, sell, sell."
Alarmed at the inaction, Zayas quit AstraZeneca and filed a whistleblower lawsuit against the firm, alleging it concealed the true cardiac risks of Seroquel when taken with certain other medications....
Our leadership, (click here) which includes our Board of Directors and Senior Executive Team, is accountable to our shareholders for the responsible conduct of the business and our long-term success. It also represents the interests of all our stakeholders in ensuring that we deliver for patients by putting science at the heart of everything we do....
March 21, 2013
By Matthew Goodman
It would have to be his predecessor responsible for mismanaging Seroquel.
Member of the Board and CEO since October 2012.
Astra Zeneca (click here) is mission impossible. It’s a giant, old-fashioned pharmaceuticals company whose best drugs are rapidly coming off patent, and whose scientists are struggling to produce new ones. Who would take a hospital pass and become its chief executive?
Step forward Pascal Soriot, a Frenchman who trained as a vet and now calls Australia home. “A number of people looked at me and thought, ‘Are you crazy?’” he admits.
Soriot, 53, was parachuted in last October to succeed David Brennan and has spent his first few months trying to come up with a cure for Astra’s ills....
Our leadership, (click here) which includes our Board of Directors and Senior Executive Team, is accountable to our shareholders for the responsible conduct of the business and our long-term success. It also represents the interests of all our stakeholders in ensuring that we deliver for patients by putting science at the heart of everything we do....
By Matthew Goodman
It would have to be his predecessor responsible for mismanaging Seroquel.
Member of the Board and CEO since October 2012.
Astra Zeneca (click here) is mission impossible. It’s a giant, old-fashioned pharmaceuticals company whose best drugs are rapidly coming off patent, and whose scientists are struggling to produce new ones. Who would take a hospital pass and become its chief executive?
Step forward Pascal Soriot, a Frenchman who trained as a vet and now calls Australia home. “A number of people looked at me and thought, ‘Are you crazy?’” he admits.
Soriot, 53, was parachuted in last October to succeed David Brennan and has spent his first few months trying to come up with a cure for Astra’s ills....
